



Signalife

Clear Data. Trusted Results.

Signalife, Inc.
531 South Main St. ~ Suite 301
Greenville, SC 29601
T 864.233.2300
F 864.233.2100
www.signalife.com
info@signalife.com

PRESS RELEASE

Monday April 16, 2007 9:38 am ET

Signalife Completes Phase One of Its Distribution Strategy

GREENVILLE, S.C., April 16 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News)

Signalife announces it has hired a new distribution organization for its Fidelity 100 product line. The group consists of independent distributor reps for cardiac rhythm management products (ICD's and pacemakers). The initial focus will be the Southern region from North Carolina to Texas, but additional representation is already under consideration in other areas of the country. The initial number of sales representatives will start at 25 and may increase to 50 before year end.

"This is a very exciting development for Signalife as the independent representatives are experienced and understand the significance of our technology and product. They have existing relationships with physicians and hospitals that mirror the desired call points for our company. We are pleased to complete phase one of this distribution channel, and look forward to results created by a professional sales force within the industry," stated Pamela Bunes, CEO of Signalife, Inc.

About Signalife, Inc.

Signalife, Inc. engages in the research, development, and marketing of signal-monitoring devices for detecting diseases. It primarily offers patient modules that are used as part of a heart monitor system to acquire, amplify, and process physiological signals associated with a patient's cardiovascular system. Signalife is based in Greenville, South Carolina. For more information visit <http://www.signalife.com>.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward-looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.

Source: Signalife, Inc.

Contact: Kevin Kading 212-918-4606

###